Unipolar Depression and the Progression of Coronary Artery Disease:Toward an Integrative Model by Ormel, Johan & de Jonge, Peter
  
 University of Groningen
Unipolar Depression and the Progression of Coronary Artery Disease





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2011
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Ormel, J., & de Jonge, P. (2011). Unipolar Depression and the Progression of Coronary Artery Disease:
Toward an Integrative Model. Psychotherapy and psychosomatics, 80(5), 264-274.
https://doi.org/10.1159/000323165
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Special Article 
 Psychother Psychosom 2011;80:264–274 
 DOI: 10.1159/000323165 
 Unipolar Depression and the Progression 
of Coronary Artery Disease: Toward an 
Integrative Model 
 Johan Ormel  a    Peter de Jonge  a–c 
 a   Interdisciplinary Center for Psychiatric Epidemiology (ICPE), Department of Psychiatry, and  b   Department of 
Internal Medicine, University Medical Center Groningen, University of Groningen,  Groningen ;  c   Center of Research 
on Psychology and Somatic Diseases (CoRPS), Department of Medical Psychology, Tilburg University,  Tilburg ,
The Netherlands 
meaning (cognitive/affective type) of the ACS to a largely 
indirect causal factor in the progression of CAD. (3) The most 
plausible pathways mediating the effects of persistent/re-
current depression, irrespective of type, on cardiac progno-
sis are behavioral and act by making depressed CAD patients 
more susceptible to other CAD risks. The model offers test-
able predictions and explanations for a variety of apparently 
unrelated or inconsistent findings.  Conclusion: The pro-
posed model may have potential for integrating findings re-
garding the depression-CAD relationship, contributing to 
the clarification of discords on screening and treatment of 
depression, and guiding future research. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Despite extensive research on the association between 
depression and the development and progression of coro-
nary artery disease (CAD), the causal significance of the 
relationship remains unclear. Recent publications in top 
medical and psychiatric journals  [1–5] show that this un-
certainty has contributed to confusion over the useful-
ness of screening and optimal treatment for depression in 
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 Abstract 
 Background: Despite extensive research on the relationship 
between depression and coronary artery disease (CAD) after 
an acute coronary syndrome (ACS), causal interpretations 
are still difficult. This uncertainty has led to much confusion 
regarding screening and treatment for depression in CAD 
patients.  Method: A critical and conceptual analysis of the 
pertinent literature, which elaborates the implications of the 
heterogeneity in symptom pattern, etiology, and course of 
depression in CAD patients.  Results: We propose an integra-
tive dynamic model of the depression-CAD relationship. The 
model rests on three core hypotheses: (1) Depression in CAD 
patients consists of mixtures of two types of depression, de-
noted as ‘cognitive/affective’ and ‘somatic’ depression, each 
having a somewhat characteristic symptom expression and 
etiology. (2) Effects of depression on CAD depend on the 
type and duration of depression. The dynamic aspect of the 
model indicates that post-ACS depression shifts, when it 
persists, from a marker of the severity (somatic type) and 
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CAD patients. Because CAD and depression will soon 
carry the largest burden of disease, understanding their 
relationship is more important than ever. 
 Research has implicated depressive disorder as both 
an etiologic and prognostic risk factor in CAD. Studies of 
depression in the context of CAD typically include the 
DSM-IV categories of major depressive disorder, minor 
depression, dysthymic disorder, and depressive disorder 
not otherwise specified. Reviews of  etiological  studies 
that look for signs of CAD in healthy depressed and non-
depressed individuals conclude that depression is an in-
dependent (i.e., causal) risk factor in CAD development 
 [6–11] . But some authors point out that few studies have 
controlled for possible subclinical atherosclerosis, e.g. 
Stewart et al.  [12] . 
 Reviews of nearly three dozen  prognostic studies show 
less consensus. These studies typically follow CAD pa-
tients with a recent acute coronary syndrome (ACS) to 
monitor the course of the disease, with mortality or CAD 
events as outcomes  [9, 10, 13–16] . Most reviews conclude 
that depression is a risk factor for CAD prognosis. But 
some have questioned the causal interpretation  [10, 15] 
or arrived at an undecided position  [16] . In addition, 
knowledge about depression and CAD is largely derived 
from studies in developed countries. The results from 
the international INTERHEART study and, to a lesser 
extent, the World Mental Health Surveys suggest sub-
stantial cross-cultural consistency in associations  [17, 
18] .
 The critique of a causal interpretation is threefold  [10, 
15, 19, 20] : (1) insufficient adjustment for accurately mea-
sured plausible confounders, in particular the severity of 
atherosclerosis and ACS, (2) reverse causality (i.e., it is
the atherosclerosis or ACS that leads to depression), and 
(3) negative or inconclusive findings of randomized con-
trolled trials on the effects of depression treatment on 
cardiac prognosis in post-ACS patients  [21–23] . To date, 
no study using randomized comparisons has found a de-
creased cardiovascular risk in post-ACS patients treated 
with antidepressants or psychotherapy. Some researchers 
have suggested cardiac benefits for patients receiving or 
responding to antidepressive treatment  [24–28] , but these 
findings are based on nonrandomized comparisons. New 
empirical studies continue to find significant etiologic 
 [29, 30] and prognostic  [31, 32] associations between de-
pression and CAD. But these findings have not silenced 
the doubts. 
 This paper integrates available evidence to formulate 
a model of the relationship between post-ACS depres-
sion and the progression of CAD. The model rests on 
three key hypotheses  [33–35] . The first hypothesis is 
that depression comorbid with CAD is a mixture of two 
prototypical types of depression: ‘cognitive/affective’ 
and ‘somatic/affective’. The second hypothesis posits 
that the nature and course of the depression affects its 
relationship with CAD progression. The third hypoth-
esis argues that behavioral mediations best explain the 
effects of depression on cardiac prognosis – with de-
pressed CAD patients being more susceptible to other 
CAD risks. 
 We first explore the assumptions and present support-
ive and conflictive evidence. Next, we derive some test-
able predictions from the model and discuss how it ac-
commodates and integrates apparently inconsistent and 
puzzling findings. Finally, we discuss its relevance for 
screening, treatment, and future research. Despite some 
supportive evidence, the three key hypotheses proposed 
clearly need further testing. 
 Post-Myocardial Infarction Depressions
Are Mixtures of ‘Cognitive/Affective’ and
‘Somatic/Affective’ Depressions 
 Depression is a highly heterogeneous syndrome char-
acterized by at least 2 weeks of depressed mood and/or 
loss of interest and a number of associated symptoms. 
DSM-IV major depression requires the presence of 5 out 
of 9 symptoms. The heterogeneity is clearly shown by
the strongly varying patterns of relationships of these 9 
symptoms with all kinds of validators including person-
ality, demographics, clinical and prognostic characteris-
tics  [36] . Refining the diagnostic category of depression 
is generally seen as highly relevant and extremely chal-
lenging. Historically, many have attempted to type de-
pression in terms of symptom pattern and etiology. Im-
portant distinctions of depression in the DSM-IV in-
volve severity, duration, recurrence, melancholic and 
atypical features, and a residual category of depressive 
disorder not otherwise specified. Lichtenberg and Bel-
maker  [37] recently distinguished 10 types of depression, 
arguing that subtyping will improve treatment effective-
ness. 
 Latent class methods often show multiple classes that 
differ in severity and core symptoms (typical versus atyp-
ical)  [38] . A recent study of 818 persons with a DSM-IV 
diagnosis of current depression identified three classes in 
the 16 depressive symptoms from the Composite Interna-
tional Diagnostic Interview: severe melancholic, severe 
atypical, and moderately severe depressions  [39] . Factor-
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analytic and item response methods to type depression 
symptoms commonly suggest three-dimensional struc-
tures, including ‘cognition/mood’ and ‘arousal/somatic’ 
 [36, 40, 41] . 
 Cognitive/Affective versus Somatic/Affective 
Symptoms 
 Similar dimensions found in depressed CAD and ACS 
patients are usually labeled as ‘cognitive/affective’ versus 
‘somatic/affective’  [12, 42–48] . Their prototypical symp-
toms are listed in  table 1 . Nearly all studies report that the 
somatic/affective dimension is associated with a less fa-
vorable cardiac prognosis. Most measured depression 
with BDI- or DSM-IV-based self-report measures, such 
as the Patient Health Questionnaire. 
 Not all evidence supports the notion of these proto-
types. Using advanced psychometrics, Doyle et al.  [49] 
showed that common somatic depression symptoms (e.g., 
fatigue) and less-common cognitive depression symp-
toms (e.g., hopelessness) form a strong one-dimensional 
scale, ordered in a hierarchy reflecting their prevalence. 
However, the only somatic items measured were fatigue 
and exhaustion; symptoms regarding appetite, weight, 
and retardation/agitation were not included.
 Somatic/affective depression shares symptoms with 
atypical depression as defined by DSM-IV. Recent studies 
suggest that the symptoms driving atypical depression 
may be more related to somatic or metabolic conditions 
than interpersonal sensitivity and mood reactivity, with 
appetite and weight increase possibly playing a key role 
 [39, 50] . Therefore, the overlap between somatic/affective 
depression and atypical depression may even be larger. 
 The two prototypes of post-ACS depression are associ-
ated with distinct characteristics, pointing at partially 
different etiologies ( fig. 1 )  [51–53] . Because post-ACS de-
pression etiology was examined without distinguishing 
the two prototypes, the evidence is limited and largely 
indirect. 
 Etiology of ‘Typical Depression’ 
 The etiology of typical depression is characterized by 
a combination of vulnerability and stressful life events, in 
particular loss of affection, skill or capacity, status, self-
esteem, cherished belief, or the threat of such losses  [54–
Table 1.  Prototypical symptoms of the cognitive/affective and

















Sleep problems (mostly more sleep)
Aches and pains
Appetite disturbance (mostly increased appetite)
Weight disturbance (mostly weight gain)
Depressed mood




















Loss of (or threat of )
- Good health
- Functional capacities
- Sense of stability
   and predictability
- Social contacts
 Fig. 1. Prototypical etiology of the cogni-
tive/affective and somatic subtypes of de-
pression in ACS patients. ANS = Autono-
mous nervous system. 
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58] . As with other disease events, experiencing an ACS 
may involve loss of belief in one’s good health, uncertain-
ty about the future, (expected) functional impairments, 
and loss of social contacts  [59–61] . The vulnerability con-
sists of personality characteristics in the domains of neu-
roticism and stress sensitivity  [56, 62, 63] , avoidant and 
catastrophizing appraisal and coping tendencies  [64, 65] , 
and particular genotypes  [66] . Loss-provoked depres-
sions have symptom profiles that are marked by high lev-
els of sadness, anhedonia, and guilt  [67] . 
 Etiology of ‘Somatic Depression’ 
 The etiology of somatic/affective depression is not 
known. One reason is the lack of a clear distinction be-
tween DSM-IV atypical depression, vascular depression 
 [68, 69] , late-onset depression  [70, 71] , somatic/affective 
post-ACS depression  [42, 46, 47] , vital exhaustion syn-
drome  [72] , and the neurovegetative symptom cluster  [73, 
74] . For ease of communication, we denote this family of 
depression types collectively as somatic depression. Major 
etiological pathways are postulated to be the presence of 
vascular disease, systemic inflammation and atheroscle-
rosis  [68, 73, 75–78] . High levels of pro-inflammatory cy-
tokines and other immune signals – especially interleu-
kin-1 and -6, tumor necrosis factor, C-reactive protein 
may induce sickness behavior  [75–77, 79] and vital ex-
haustion  [29, 80, 81] , which both produce many symptoms 
of somatic depression. Deregulated hypothalamic pitu-
itary-adrenal axis functioning (hyper- or hypocorti-
solemia) may also be involved in the etiology of somatic 
depression, although its role is less clear  [82] . Other stud-
ies link autonomic nervous system dysfunction to somat-
ic depression  [83–85] . Of interest, a reanalysis of data from 
the Heart and Soul Study showed that somatic symptoms 
of depression were associated with reduced heart rate 
variability, whereas cognitive symptoms and overall de-
pression were not  [27] . Finally, disturbed central sero-
tonin transmission has been associated with hypothalam-
ic abnormalities that may contribute to altered appetite 
and decreased libido, and thalamic and brainstem dys-
regulations are thought to contribute to altered sleep  [86] . 
 Although suggestive, the evidence on the etiology of 
somatic depression is not consistent. For instance, the 
Heart and Soul Study found lower levels of C-reactive 
protein, fibrinogen, and interleukin-6 in depressed CAD 
patients  [87] . A consistent but regularly ignored finding 
is that inflammation and atherosclerosis are found only 
in a subset of depressions  [88] , typically late-onset de-
pressions  [89, 90] .
 Different Courses 
 The course of ACS-triggered cognitive/affective 
symptoms is, we hypothesize, usually favorable, un-
less psychological vulnerabilities and disabilities are 
marked. Patients with no history of major depression 
and with a stable condition free from serious complica-
tions or severe impairment tend to adapt to chronic ill-
ness, and their depression resolves accordingly  [91, 92] . 
CAD-associated somatic depressions are likely to per-
sist because the ongoing CAD and underlying athero-
sclerosis and systemic inflammation will continue to 
fuel the etiology. Consequently, we hypothesize that the 
course of somatic depression as related to CAD will be 
less favorable than the cognitive/affective symptom 
cluster – unless the underlying physiological causes 
change for the better.
 Continuous Transitions between Prototypes 
 Any mixture of cognitive/affective and somatic de-
pression may develop in a particular individual with 
(subclinical) CAD. Both clusters may be present at the 
same time, especially after a major ACS having simulta-
neous psychological and physical impact. Also, the case 
mix of cognitive/affective and somatic depression may 
differ considerably among patient samples depending on 
the prevalence and severity of CAD and other atheroscle-
rotic-related chronic physical conditions. 
 Effects of Depression on CAD Depend on Type and 
Duration 
 The second hypothesis posits that the effects of de-
pression on CAD prognosis depend on type and course 
of depression. Duration is important because influences 
on behavioral and other pathways accumulate with time. 
We propose several predictions ( table 2 ).
 (1) Brief cognitive/affective depression is at most only 
weakly associated with CAD prognosis because the psy-
chological meaning of the ACS probably depends some-
what on the biomedical severity of the ACS. Since the 
CAD prognosis also depends on ACS severity (the con-
founder), some causally spurious statistical association 
between cognitive/affective depression and CAD prog-
nosis may result.  
 (2) In contrast, brief somatic depression is more 
strongly associated with CAD prognosis, due to con-
founding effects of ACS severity and underlying CAD, 
atherosclerosis, and associated physiological abnormali-
ties (e.g., inflammation, endothelial dysfunction). These 
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physical factors may be involved in both somatic depres-
sion and CAD prognosis. Consequently, we hypothesize 
that the association of brief somatic depression with CAD 
prognosis is (largely) spurious. Evidence that nonadjust-
ed risks of depression substantially decrease when adjust-
ed for the ACS and CAD supports these predictions  [10, 
16, 93, 94] .  
 (3) If persistent, we expect both types of depression 
to be associated with CAD prognosis, with the somatic 
link being stronger. The more persistent or recurrent the 
course of either type of depression, the more negative 
effects of persistent depression accumulate – making 
both types relevant for CAD prognosis (see hypothesis 
3 below)  [17, 24, 95–97] . Thus, when post-ACS depres-
sion persists, it shifts slowly from a marker of the sever-
ity (somatic type) and meaning (cognitive/affective 
type) of the CAD to a contributing factor in the progres-
sion of CAD.  
 Research has not yet examined the independent effects 
of type and duration on CAD prognosis, so we have no 
direct evidence related to these predictions. But they ap-
pear to be indirectly supported by the less favorable car-
diac prognosis typically found only for somatic symp-
toms  [12, 42, 43, 46] . In addition, depression persistence 
and/or treatment resistance are associated with longer 
episode duration  [98, 99] and a poor CAD prognosis  [2, 
27] . Finally, the longer-term effects of depression on CAD 
are mediated by chronic/recurrent depression  [100] . 
 Significance of Behavioral Pathways in the Effects of 
Depression on CAD Prognosis 
 The third hypothesis addresses the pathways through 
which depression influences CAD prognosis. Regardless 
of type, plausible pathways mediating the effects of  per-
sistent/recurrent depression on cardiac prognosis seem to 
be behavioral and thus indirect by making depressed 
CAD patients more susceptible to other CAD risks. 
Among these risks are nonoptimal CAD treatment  [101] , 
nonadherence to CAD treatment  [102] and rehabilitation 
programs  [103] , and unhealthy lifestyle, including smok-
ing, poor diet, and limited physical activity  [104] . The 
consequences of the interplay between cognitive/affec-
tive and somatic symptoms and behavioral pathways may 
be substantial. Symptoms such as anhedonia, hopeless-
ness, lethargy, and psychomotor slowing may promote 
decreased physical activity, lower treatment adherence, 
overeating. 
 The limited evidence available clearly supports a role 
for behavioral pathways. For example, Druss et al.  [101] 
used medical charts and administrative files to compare 
the health care utilization of post-myocardial infarction 
patients with and without mental disorders. Patients with 
diagnosed affective disorder were significantly less likely 
to undergo cardiovascular procedures. Differences in 
medical (co)morbidity did not explain the lower rate of 
cardiovascular procedures in these patients. 
 In addition, depressed post-ACS patients have exhib-
ited higher rates of nonadherence and dropout in CAD 
treatment regimens and cardiac rehabilitation  [103, 105] . 
An important and effective component of rehabilitation 
programs is physical exercise, which also seems to have 
beneficial effects on depression  [106, 107] . Behavioral ac-
tivation is regarded as an effective way to promote physi-
cal exercise and improve depressive symptoms  [108] . The 
strongest evidence to date comes from the Heart and Soul 
Study of stable CAD patients  [104] . Lifestyle factors, in 
particular physical activity, accounted for almost 50%
of the association between depression and new cardiac 
events. In contrast, physiological factors were unrelated 
to or only minimally associated with new cardiac events. 
Table 2.  Strength and nature of association between post-ACS depression and CAD prognosis by type and duration of depression
Type of depression D uration of depression
brief (remission within 6  months) persistent (chronic/recurrent)
Cognitive-affective none or weak association (noncausal) due to the weak 
association between severity of ACS and CAD and their 
psychological meaning 
significant association due to
accumulating negative effects on
health behavior
Somatic substantial but largely spurious association, due to
confounding influences by severity of CAD and
underlying atherosclerosis
strong association due to ongoing
confounding plus accumulating
negative effects on health behavior
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 Integrative Model of the Depression-CAD 
Relationship  
 Figure 2 summarizes the integrative model of the de-
pression-CAD relationship. The model posits effects of 
depression on CAD and ACS outcomes as well as effects 
of CAD and ACS on depression. In both relationships, the 
effects depend on type and duration. The model hypoth-
esizes that CAD, with its underlying atherosclerosis, is a 
risk factor for somatic depression but less so for cognitive/
affective depression. The reverse holds for ACS and initial 
CAD diagnosis. Atherosclerosis usually takes decades 
before causing clinical symptoms, so it may affect the risk 
of somatic depression long before the cardiologist diag-
noses CAD. 
 Recently, the potential role of atherosclerosis in the 
dynamic bidirectional relationship between depression 
and CAD has been emphasized  [2, 88, 109, 110] . Athero-
sclerosis-related systemic inflammation is probably in-
volved in the etiology of somatic depression, while de-
pression may affect the atherosclerotic process via its 
influence on CAD risks of smoking, diet, physical activ-
ity, and treatment adherence. Taken together, this leads 
to a complex cause-and-effect relationship that may be 
best described as a dynamic spiral of reciprocal influ-
ences  [111] , unfolding on a time scale of decades  [75, 
110] . 
 Some Limitations  
 The model does not currently account for depression 
having symptomatic overlap and lifetime and concurrent 
comorbidity with anxiety disorders. Few studies have ex-
amined the relationship between anxiety and CAD, and 
most did not assess diagnosis  [11] . Recent work suggests 
that both anxiety symptoms and generalized anxiety dis-
order are associated with the presence of CAD and an 
increased risk of adverse cardiac events in patients with 
stable CAD  [32, 112] . The model does not imply that the 
depressive types in ACS patients are unrelated to anxiety 
disorder, but we cannot exclude the possibility that anxi-
ety is driving the association. A related point is neuroti-
cism, which is common to most anxiety and depressive 
disorders and associated with an increased risk of somat-
ic symptoms  [11] . 
 How the Theory Integrates Apparently Inconsistent 
and Unrelated Findings 
 The model explains some apparently unrelated or in-
consistent findings.
First, large randomized controlled trials of standard 
depression treatment such as antidepressants and cogni-
tive behavioral therapy in recent-ACS patients have not 

























 Fig. 2. Schematic overview of the relation-
ships between depression and the progno-
sis of CAD. 
 Ormel  /de Jonge   Psychother Psychosom 2011;80:264–274 270
could not determine whether effective treatment of de-
pression improves CAD prognosis  [21, 23, 113] . Accord-
ing to the model, this lack of effect may be due to the pre-
ponderance of somatic depression (typically resistant to 
standard depression treatments) in the case mix and the 
lack of cardiotoxicity of cognitive/affective depression of 
relatively brief duration. The proportion of treatment-re-
sponsive cognitive/affective depressions of long duration 
(and therefore slowly becoming cardiotoxic) in the case 
mix was probably too small or the improvement too min-
imal to have a significant effect on CAD prognosis.
 Second, secondary analyses of clinical trials of depres-
sion in ACS patients identify two subgroups of patients 
with high cardiac risk: (i) those with unsuccessfully treat-
ed depression and (ii) those with high severity of de-
pression soon after admission for ACS  [2, 24, 27, 114; 
Frasure-Smith, personal commun., reported in  25 ]. The 
proposed model is consistent in asserting that most
treatment-resistant depressions consist of somatic de-
pressions. The reason these depressions do not respond 
well to standard depression treatments is probably their 
physiological CAD-related etiology. In addition, treat-
ment resistance is associated with longer episode dura-
tion  [98, 99] , which fuels accumulation of behavioral 
risks, and, in turn, worsens CAD prognosis. This accu-
mulation applies to both depression types, if persistent. 
Notably, the second finding – which links ACS-related 
depression severity with CAD prognosis – may be due to 
confounding by the severity of the ACS, underlying ath-
erosclerosis, and associated inflammation. 
 Third, analyses by Glassman et al.  [2, 115] demon-
strate that certain subgroups of depressed CAD patients 
may benefit from antidepressant medication (sertraline, 
citalopram): those whose current depression episode be-
gan before the ACS, those with a history of depression, 
and those with the most severe episodes. Others have re-
ported somewhat similar findings  [3, 26, 114] . According 
to the model, these findings make sense if cognitive/af-
fective symptoms characterize most episodes in these 
subgroups. This is plausible given the response to stan-
dard depression treatment and the history and pre-ACS 
onset of the episodes.
 Fourth, multiple studies have examined the relation-
ship between inflammatory markers and major depres-
sion. Although most published studies found some 
 increased inflammation in depressed patients, many 
 exceptions have been reported  [73, 75, 88] . The contra-
dictory findings could be due to differences in case mix, 
especially related to the proportion of somatic depression 
in the study samples. This would also account for the ob-
servation that late-onset depression is associated with in-
flammation markers and atherosclerosis, whereas early-
onset depression is not  [89, 90] . 
 Clinical Implications 
 The integrative model can reconcile some differences 
of opinion on screening and treatment of depression in 
ACS patients and help find and develop promising inter-
ventions for new randomized controlled trials. Some 
scholars discourage routine screening because there is 
little evidence that it produces better outcomes in CAD 
patients  [1] . On the other hand, an advisory group from 
the American Heart Association Prevention Committee 
 [116] proposed screening all post-ACS patients for de-
pression at regular intervals during the post-ACS period, 
including during hospitalization, using a standardized 
depression symptom checklist. The debate has also led to 
different treatment suggestions. Some urge for aggressive 
standard treatment of depression in ACS patients  [3, 114] , 
while others advocate a more conservative approach  [1] 
or a focus on interventions seeking to improve adherence 
to cardiac rehabilitation, stress management, and life-
style changes  [104] . 
 Acknowledging the etiological heterogeneity and the 
negative health behavior effects of persistent depression 
may help resolve this debate. The model predicts that 
standard depression treatments will probably be ineffec-
tive for somatic depressions because of their atypical eti-
ology and underlying neurophysiology. Standard depres-
sion treatments must lead to significant improvement in 
CAD risk factors in order to normalize atherosclerosis- 
and CAD-associated abnormalities, including increased 
systemic inflammation, platelet activation (except selec-
tive serotonin reuptake inhibitors), endothelial dysfunc-
tion, reduced heart rate variability, and baroreceptor sen-
sitivity  [117] . If most depressions in ACS patients consist 
of the somatic type, screening seems problematic since 
somatic depression has no clearly effective treatment yet. 
 For persistent depression that is largely cognitive/af-
fective, the model predicts that successful treatment 
might improve CAD prognosis via health behavior. With 
moderately effective treatments for cognitive/affective 
depression available  [118, 119] , screening may ultimately 
enhance the likelihood of successful treatment, provided 
that screening tools are not overinclusive and that effec-
tive treatment follows positive screening. Given the hy-
pothesized tendency of post-ACS cognitive/affective de-
pressions to improve spontaneously, it seems cost-effec-
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tive to have a waiting period of 1 or 2 months to exclude 
spontaneous remissions or to start low-intensity psycho-
social treatment (by a nurse practitioner for instance) in 
order to speed up ‘spontaneous’ remission.
 If the depression is largely somatic, it seems more ef-
fective to directly target health behaviors and adherence 
to cardiac treatment, including cardiac rehabilitation and 
physical exercise. Those interventions may reduce car-
diac risk factors and be the most effective strategy for 
improving long-term CAD and, indirectly, the somatic 
depression as well  [106, 120] , since its symptoms are fu-
elled by the CAD, underlying atherosclerosis, and associ-
ated physiological abnormalities. If these risk factors im-
prove, the somatic symptoms may decrease in severity. 
Thus, aggressive treatment of cardiac risk factors such as 
poor lifestyle and physical inactivity may also be the best 
treatment currently available for somatic depression. Re-
cent evidence suggests that exercise may be effective in 
treating both depression and CAD risk factors  [107, 120] . 
If physical exercise and lifestyle interventions are effec-
tive for both somatic and cognitive/affective depression, 
they will be essential treatments in post-ACS depression 
as they would treat both the depression and help with the 
cardiac risk factors. 
 Future Directions 
 First, the core hypotheses of the model theory need 
further testing. To some extent, this can be achieved by 
(i) refining the measurement of depression (e.g., type, his-
tory, etiology, duration)  [37, 119] , (ii) documenting ath-
erosclerosis and its progression, (iii) prospective research 
designs that carefully monitor depression and CAD out-
comes, and (iv) including measures of plausible behav-
ioral (e.g., exercise) and physiological (e.g., inflammation 
markers) pathways through which the CAD effects of de-
pression may be mediated. Such research will help pin-
point the cardiotoxic aspects of depression, the precise 
nature of the harmful CAD effects, and the mechanistic 
pathways that link depression to CAD progression. In ad-
dition, it is important to acknowledge the heterogeneity 
of depression  [37, 119] and elucidate the characteristics of 
the depressions and patients that benefit from particular 
treatments  [114] . This way depression type- and person-
tailored interventions can be developed and evaluated. 
 Future research on the depression-CAD relationship 
will need to integrate psychological, behavioral, physio-
logical, and neurobiological findings and to combine ep-
idemiological, clinical, and experimental methods. What 
we have now are interesting pieces of a complicated jigsaw 
puzzle, but the pieces have yet to be assembled in a way 
that allows us to make progress beyond inconsistent find-
ings and speculation and towards insights in causal pro-
cesses and some measure of certainty. We hope the pro-
posed integrative model will contribute to these goals. 
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